ConductScience.org, home

Paper2390468

Thyroiditis after treatment with interleukin-2 and interferon alpha-2a.

Pichert G and 5 others. Br J Cancer, 1990. Cited by 77 papers, by iCite.

Cite this record

ConductScience Library. Thyroiditis after treatment with interleukin-2 and interferon alpha-2a. Papers, record 2390468. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/2390468

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Thyroiditis after treatment with interleukin-2 and interferon alpha-2a.
PubMed
Journal
Br J Cancer
PubMed
Year
1990
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
77
iCite
Relative citation ratio, by iCite
2.75
iCite
Revised in PubMed
2019-05-15
PubMed

Authors6

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Pichert GG
2Jost LML M
3Zöbeli LL
4Odermatt BB
5Pedia GG
6Stahel RAR A

Source PubMed

Download CSV of authors

Topics20

NLM's MeSH indexing of the paper, its major topics first.

MeSH termMajor
Interferon Type IMajor topic
Interferon-alphaMajor topic
Interleukin-2Major topic
ThyroiditisMajor topic
Adult
Carcinoma, Renal Cell
Drug Therapy, Combination
Female
Humans
Immunity, Cellular
Immunohistochemistry
Interferon alpha-2
Kidney Neoplasms
Male
Melanoma
Middle Aged
Prospective Studies
Recombinant Proteins
Thyroid Gland
Thyrotropin

Source PubMed

Download CSV of topics

References19

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
1371875Goitrous autoimmune thyroiditis (Hashimoto's disease).Clin Endocrinol Metab1979https://conductscience.org/library/papers/371875PubMed
22502555Influence of tumor necrosis factor-alpha on the modulation by interferon-gamma of HLA class II molecules in human thyroid cells and its effect on interferon-gamma binding.J Clin Endocrinol Metab1989https://conductscience.org/library/papers/2502555PubMed
36138647Role of aberrant HLA-DR expression and antigen presentation in induction of endocrine autoimmunity.Lancet1983https://conductscience.org/library/papers/6138647PubMed
43930110Interferon-gamma induces HLA-DR expression by thyroid epithelium.Clin Exp Immunol1985https://conductscience.org/library/papers/3930110PubMed
52944910Thyroid autoimmunity in patients on long term therapy with leukocyte-derived interferon.J Clin Endocrinol Metab1986https://conductscience.org/library/papers/2944910PubMed
63493432A progress report on the treatment of 157 patients with advanced cancer using lymphokine-activated killer cells and interleukin-2 or high-dose interleukin-2 alone.N Engl J Med1987https://conductscience.org/library/papers/3493432PubMed
73495802Hyperinducibility of Ia antigen on astrocytes correlates with strain-specific susceptibility to experimental autoimmune encephalomyelitis.Proc Natl Acad Sci U S A1987https://conductscience.org/library/papers/3495802PubMed
83115656Enhanced production of gamma-interferon by thyroid-derived T cell clones from patients with Hashimoto's thyroiditis.Clin Exp Immunol1987https://conductscience.org/library/papers/3115656PubMed
93499823The immunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlation of response with T-cell infiltration and HLA-DR expression.Am J Pathol1987https://conductscience.org/library/papers/3499823PubMed
103258138Metastatic renal cancer treated with interleukin-2 and lymphokine-activated killer cells. A phase II clinical trial.Ann Intern Med1988https://conductscience.org/library/papers/3258138PubMed
112452856Predominant expression of a T cell receptor V beta gene subfamily in autoimmune encephalomyelitis.J Exp Med1988https://conductscience.org/library/papers/2452856PubMed
123286117Autoimmune thyroid disease: immunological, pathological, and clinical aspects.Crit Rev Clin Lab Sci1988https://conductscience.org/library/papers/3286117PubMed
133259674Hypothyroidism after treatment with interleukin-2 and lymphokine-activated killer cells.N Engl J Med1988https://conductscience.org/library/papers/3259674PubMed
143139285Circulating cytokines in patients with metastatic cancer treated with recombinant interleukin 2 and lymphokine-activated killer cells.Cancer Res1988https://conductscience.org/library/papers/3139285PubMed
152460358An autoimmune aetiology for hypothyroidism following interferon therapy for breast cancer.Eur J Cancer Clin Oncol1988https://conductscience.org/library/papers/2460358PubMed
162647913A phase II study of interleukin-2 and lymphokine-activated killer cells in patients with metastatic malignant melanoma.J Clin Oncol1989https://conductscience.org/library/papers/2647913PubMed
172785167Hypothyroidism after interleukin-2 therapy.J Clin Oncol1989https://conductscience.org/library/papers/2785167PubMed
182787749Tolerance and effectiveness of recombinant interleukin-2 (r-met Hu IL-2 [ala-125]) and lymphokine-activated killer cells in patients with metastatic solid tumors.Eur J Cancer Clin Oncol1989https://conductscience.org/library/papers/2787749PubMed
196138646Aberrant expression of HLA-DR antigen on thyrocytes in Graves' disease: relevance for autoimmunity.Lancet1983https://conductscience.org/library/papers/6138646PubMed

Download CSV of references

Cited by15

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 77 citations.

PMIDTitleJournalYearIn PapersSource
42891082Immunocytokines in cancer: a safety perspective.Front Immunol2026https://conductscience.org/library/papers/42891082PubMed
25294906MHC class I loss is a frequent mechanism of immune escape in papillary thyroid cancer that is reversed by interferon and selumetinib treatment in vitro.Clin Cancer Res2014https://conductscience.org/library/papers/25294906PubMed
22010182Thyroid dysfunction from antineoplastic agents.J Natl Cancer Inst2011https://conductscience.org/library/papers/22010182PubMed
17372828A case of hyperthyroidy developing in "pegylated-interferon" therapy.Dig Dis Sci2007https://conductscience.org/library/papers/17372828PubMed
11051216Drug-induced rheumatic disorders: incidence, prevention and management.Drug Saf2000https://conductscience.org/library/papers/11051216PubMed
9972674Occurrence of thyroid autoimmunity and dysfunction throughout a nine-month follow-up in patients undergoing interferon-beta therapy for multiple sclerosis.J Endocrinol Invest1998https://conductscience.org/library/papers/9972674PubMed
8264254Low dose cyclophosphamide, alpha-interferon and continuous infusions of interleukin-2 in advanced renal cell carcinoma.Med Oncol Tumor Pharmacother1993https://conductscience.org/library/papers/8264254PubMed
8061797Development of transient thyroid disease and reaction during treatment of chronic hepatitis C with interferon.J Gastroenterol1994https://conductscience.org/library/papers/8061797PubMed
7824050Effects of type I-interferons on human thyroid epithelial cells derived from normal and tumour tissue.Naunyn Schmiedebergs Arch Pharmacol1994https://conductscience.org/library/papers/7824050PubMed
7711430Suppressed thyroid-stimulating hormone secretion in patients treated with interleukin-2 and interferon-alpha 2b for metastatic melanoma.Clin Investig1994https://conductscience.org/library/papers/7711430PubMed
7693434Interleukin-2. A review of its pharmacological properties and therapeutic use in patients with cancer.Drugs1993https://conductscience.org/library/papers/7693434PubMed
7516663Clinical toxicity of the interferons.Drug Saf1994https://conductscience.org/library/papers/7516663PubMed
1997108Clinical and immune modulatory effects of alternative weekly interleukin-2 and interferon alfa-2a in patients with advanced renal cell carcinoma and melanoma.Br J Cancer1991https://conductscience.org/library/papers/1997108PubMed
1931616Thyroid dysfunction can predict response to immunotherapy with interleukin-2 and interferon-2 alpha.Br J Cancer1991https://conductscience.org/library/papers/1931616PubMed
1418698Clinical toxicity of interleukin-2.Drug Saf1992https://conductscience.org/library/papers/1418698PubMed

Download CSV of cited by

Genes4

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn GenesSource
FCGR3A2214PubTator's text mininghttps://conductscience.org/library/genes/2214NCBI Gene
IFNA23440PubTator's text mininghttps://conductscience.org/library/genes/3440NCBI Gene
IL23558PubTator's text mininghttps://conductscience.org/library/genes/3558NCBI Gene
TG7038PubTator's text mininghttps://conductscience.org/library/genes/7038NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/2390468

GET https://conductscience.org/api/papers/v1/2390468/authors